Your browser doesn't support javascript.
loading
Boron neutron capture therapy (BNCT): implications of neutron beam and boron compound characteristics.
Wheeler, F J; Nigg, D W; Capala, J; Watkins, P R; Vroegindeweij, C; Auterinen, I; Seppälä, T; Bleuel, D.
Afiliação
  • Wheeler FJ; Center for Advanced Radiation Therapies, Idaho National Engineering and Environmental Laboratory, Idaho Falls 83415-3890, USA.
Med Phys ; 26(7): 1237-44, 1999 Jul.
Article em En | MEDLINE | ID: mdl-10435523
ABSTRACT
The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal-neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well-characterized epithermal-neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR-1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p-Boronophenylaline Fructose (BPA-F) and a hypothetical next-generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal-neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy-tissue tolerance and a reduction in the hydrogen-recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR-1 beam has the better quality (lower hydrogen-recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR-1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully optimized.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radiossensibilizantes / Neoplasias Encefálicas / Compostos de Boro / Terapia por Captura de Nêutron de Boro / Frutose / Glioma Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Humans Idioma: En Revista: Med Phys Ano de publicação: 1999 Tipo de documento: Article País de afiliação: Estados Unidos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Radiossensibilizantes / Neoplasias Encefálicas / Compostos de Boro / Terapia por Captura de Nêutron de Boro / Frutose / Glioma Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Humans Idioma: En Revista: Med Phys Ano de publicação: 1999 Tipo de documento: Article País de afiliação: Estados Unidos